The rise of radiopharmaceuticals – How Australian biotech is at the forefront of this resurgence
Tracks
Track 1
| Wednesday, October 30, 2024 |
| 4:55 PM - 5:40 PM |
| Plenary Room |
Overview
Sponsored by: TELIX
Details
The global radiopharmaceuticals market is poised for significant growth, with a forecasted value of over $21 billion by 2032 and growing 10 per cent annually. Australian Biotech is at the forefront of this new wave of radiopharmaceutical innovations, set to transform patient outcomes and unlock the sector's potential.
This session highlights several key Australian listed and unlisted radiopharmaceutical biotechnology companies together with a panel session discussing some of the advantages and challenges in succeeding in one of the fastest growing sectors in precision oncology and medical science.
Speaker
Mr Stephen Rose
SVP of Translation Medicine & Clinical Science
AdvanCell
Panellist
Dr. Michael Wheatcroft
Chief Scientist
Telix Pharmaceuticals
Panellist
Ms Kyahn Williamson
Senior Vice President Investor Relations and Corporate Communications
Telix Pharmaceuticals
Panellist
